administered by powder inhaler. 3 Nebulised administration of zanamivir inhalation powder as a liquid formulation is not recommended. 
| ME THODS
All sites that had received aqueous zanamivir from the manufacturer under the compassionate use programme (CUP) between
October 2009 and January 2011 were approached by PHE or via the ICS "Linkman" network of intensive care professionals. The manufacturer provided information to responding sites to identify patients who received aqueous zanamivir treatment. Cases were defined as intensive care patients for whom parenteral zanamivir aqueous solution was provided by the manufacturer under the CUP.
Collaborators completed a standardised case report form providing anonymised demographic, clinical, microbiological, hospitalisation, treatment and outcome information including adverse events.
Sequential Organ Failure Assessment (SOFA) scores at initiation of aqueous zanamivir therapy were provided for each case. 6 Data collection began in March 2013 and was completed in March 2015.
Follow-up information was available for 457 of the 485 cases for whom parenteral zanamivir was issued.
The recommended adult dosage of intravenous aqueous zanamivir was 600 mg twice daily for 5 days; adjustments were required for renal impairment. 7 Children, adolescents and pregnant women required weight-based dosing. The recommended adult nebulised dose was 25 mg four times daily.
An adverse event was defined as any untoward medical oc- In all analyses, P values of <0.05 were considered significant.
Statistical analyses were conducted using IPython 9 and R version 3.1.3.
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Ethical approval of the study was granted for all NHS sites taking part in the study from the East of Scotland Research Ethics Service (EoSRES).
| RE SULTS
Data were returned for 185 cases (out of 457 questionnaires sent; response rate 38%). Thirty-four sites each provided data for between 1 and 21 cases (median three cases). Data completeness was >95% for the majority of key variables. Fifteen cases (8%) were pregnant; of these, 12 (80%) were in the third trimester.
| Clinical/demographic characteristics
Information on influenza vaccination status was available for only five cases (2 had received vaccination against H1N1pdm09; for 3, the vaccine was not specified).
The median SOFA score at the time of initiation of zanamivir therapy was 9 (lower and upper quartiles 7 and 13). Higher scores were recorded for the respiratory, neurological and cardiovascular domains of the SOFA score (Friedman rank sum test P value <0.0001). 
| Treatment
Most cases (164 cases; 89%) received antiviral therapy prior to aqueous zanamivir therapy (where specified, oseltamivir was given for all but two cases, who received inhaled zanamivir therapy). Duration of prior antiviral therapy was reported for 73%: 72 cases (60%) received therapy for 5 days or less, 40 cases (33%) for 6-14 days and eight cases (7%) for greater than 14 days.
The most common reasons for admission to intensive care were respiratory failure (89%), sepsis (28%) and cardiovascular failure (14%).
Most cases (90%) received intravenous zanamivir therapy alone, the remainder receiving nebulised zanamivir therapy alone or zanamivir via both routes. The duration of intravenous zanamivir therapy ranged from 1 to 21 days (median 6 days). The duration of nebulised zanamivir therapy ranged from 1 to 10 days (median 5 days). Dosage was adjusted for renal function for 27 cases (16%).
Median overall SOFA scores were higher for cases given intra- 
| Complications and adverse events
Common complications of influenza infection included acute respiratory distress syndrome (43%), bacterial pneumonia (41%) and sepsis (40%). One or more manifestations of renal, cardiovascular, hepatic, haematological, neurological and gastrointestinal compromise were seen in 70 cases (38%) during zanamivir therapy.
Scheduled dosing was interrupted during the treatment period for 17 cases (10%) and was stopped before the scheduled end of therapy in 26 cases (15%). The reason for early discontinuation of treatment was recorded for 24 cases; the reason was physician discretion for 15 cases (63%) and suspected adverse events for nine cases (38%).
A total of 163 adverse events were recorded for 81 cases (44% of all cases), of which 86 were described as serious. Twenty-four cases (13%) had adverse events which were reported as temporally related to zanamivir therapy (of which 18 events were recorded as serious, including three deaths, five events of hepatic dysfunction (including one event of hepatic failure) and four acute renal failure events).
| Mortality
Outcomes were recorded for 175 cases (95%). Of these, 97 cases (55%) recovered, 18 cases (10%) recovered with permanent sequelae and 60 cases (34%) died. Death certificate data were available for all 60 deaths. Influenza was recorded as a primary cause of death for 37 cases (62%) and pneumonia, pneumonitis, bronchopneumonia or acute respiratory distress syndrome of unspecified cause for a further nine cases (15%). For one patient, influenza was a secondary cause of death. Influenza or compatible syndromes were not recorded among the causes of death for five cases (8%).
Age group (highest relative mortality in the 55-64 years age group), cardiovascular impairment, complications of pneumonia, renal replacement therapy, corticosteroid therapy and high SOFA scores were significantly associated with mortality (Table 2) . Nonserious adverse events temporally related to zanamivir were associated with significantly reduced mortality, and serious adverse events temporally related to zanamivir were not significantly associated with mortality.
Among those who died median time to zanamivir treatment was 13 days, compared with 10 days for those who survived (P = 0.22).
| D ISCUSS I ON
This is the largest observational study of a cohort of patients with severe influenza treated with parenteral zanamivir therapy reported to date. The co-morbidities and other risk factors for severe influenza described in this cohort reflect the overall epidemiology of the H1N1pdm09 pandemic influenza virus, which disproportionately impacted younger adult age groups and those with risk factors including immunosuppression, morbid obesity and pregnancy. 1 However, the response rate was low and it is not possible to draw conclusions about the effect of parenteral zanamivir from this study. In the event of a future potential pandemic, information on novel treatments needs to be collected and analysed in real time in order to inform the response to a pandemic, using randomised, controlled trials where possible. Future evaluations of investigational products during influenza pandemics will require standardised collection of high-quality data to inform the evidence base, ideally planned in advance allowing for adequate staff training, and undertaken prospectively; a challenge that is currently being addressed by the PREPARE 24 and ISARIC 25 projects. New treatment options are urgently required to improve outcomes for patients with severe and life-threatening influenza infections.
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